Posted in Other 2 days ago.
Moderna is seeking a highly skilled and motivated Senior Research Associate in Immunology, Infectious Disease ready to function in a fast-paced and collaborative environment. This position is based at the Moderna Cambridge site and will be reporting to an Associate Scientific Director. The Senior Research Associate will help develop ex vivo and in vivo immunology assays that support the advancement of Moderna's mRNA technology platform. The individual in this role will investigate immune-related molecular and cellular mechanisms of vaccines and is responsible for lab equipment maintenance. She/he/they should be able to apply various immunological techniques and will have the ability to work in a highly collaborative, dynamic, and interdisciplinary environment. The successful candidate is expected to have substantial hands-on experience in flow cytometry acquisition and analysis, including antibody panel design.
Here's What You'll Do:
Development and performance of ex vivo/in vivo immunology-related assays
Strong flow cytometry focus and corresponding analyses
Cell-based assays including maintaining and plating of cell lines and primary cells
General laboratory assistance, including lab equipment maintenance, ordering and organizing supplies
Careful record keeping (e-lab notebook and others), data organization and presentation
Here's What You'll Bring to the Table:
BS/BA with at least 2-3 years of lab-related experience or MS focused on biological sciences 0-2 years of experience; industry experience desirable but not a must; performing in vitro screening performing in vitro/ ex vivo immunology experiments
Required: experience in immunological assays including flow cytometry, ELISA, luminescent and fluorescence-based assay development
Hands on experience with cell culture (cell lines and primary cell culture). Aseptic technique is a must. In vitro tissue model maintenance a plus.
Excellent skills and ability to work efficiently in a multicultural highly dynamic and matrixed environment
Here's What We'll Bring to the Table:
In 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the promising-but-still-unproven field of messenger RNA (mRNA), to an enterprise with its first medicine having treated millions of people, a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna's capabilities have come together to allow the authorized use of one of the earliest and most-effective vaccines against the COVID-19 pandemic.
Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Today, 24 development programs are underway across these therapeutic areas, with 13 programs having entered the clinic. Moderna has been named a top biopharmaceutical employer by Science for the past six years. To learn more, visit www.modernatx.com.
Moderna is a smoke-free, alcohol-free and drug-free work environment.
Moderna is committed to equal employment opportunity and non-discrimination for all employees and qualified applicants without regard to a person's race, color, gender, age, religion, national origin, ancestry, disability, veteran status, genetic information, sexual orientation or any characteristic protected under applicable law. Moderna will make reasonable accommodations for qualified individuals with known disabilities, in accordance with applicable law.#LI-AM1